Sign In
Buy PCSA
$2.15
+0.110 (+5.39%)
At Close: Jul 31, 2026
4 Stocks With CEO Buys in the Past Month
05:37pm, Thursday, 08'th Jul 2021
According to the CEO Buys Screen, a Premium All-in-One Screener template, four stocks that had at least three insider buys including the CEO during the past month are REV Group Inc. ( REVG , Financial
Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET
08:15am, Tuesday, 06'th Jul 2021
HANOVER, MD, July 06, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that the company will present at Access to Giving Virtual Conference. The presentation will
Processa Pharmaceuticals In-Licenses Ocuphire's Anticancer Agent
01:55pm, Thursday, 17'th Jun 2021
Processa Pharmaceuticals Inc (NASDAQ: PCSA) has entered into a licensing agreement with Ocuphire Pharma Inc (NASDAQ: OCUP) to in-license RX-3117. RX-3117 is an oral anticancer agent with an impro
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
09:15am, Thursday, 17'th Jun 2021
HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP) to
Processa Set to Join Russell Microcap® Index
09:15am, Tuesday, 08'th Jun 2021
HANOVER, MD, June 08, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to i
Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET
04:05pm, Monday, 07'th Jun 2021
HANOVER, MD, June 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to i
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
09:15am, Wednesday, 26'th May 2021
HANOVER, MD, May 26, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to im
~ Processa's trial is currently enrolling patients with ulcerated Necrobiosis Lipoidica . Detailed information on the trial can be located on clinicaltrials.gov NCT#: 04800562 .~
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 18'th May 2021
HANOVER, MD., May 18, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to i
Processa Pharmaceuticals, Inc. (PCSA) CEO David Young on Q1 2021 Results - Earnings Call Transcript
07:37am, Friday, 14'th May 2021
Processa Pharmaceuticals, Inc. (PCSA) CEO David Young on Q1 2021 Results - Earnings Call Transcript
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
04:55pm, Thursday, 13'th May 2021
Clinical drug pipeline is funded and targeting major milestones in Q2 and 2H 2021
HANOVER, MD., May 07, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to i
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
04:06pm, Thursday, 25'th Mar 2021
Clinical drug pipeline is funded and targeting major milestones in 2021
Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica
09:15am, Wednesday, 17'th Mar 2021
HANOVER, March 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical c
Processa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement
09:15am, Tuesday, 02'nd Mar 2021
HANOVER, MD, March 02, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is pleased to announce it has closed its previously announced private placement to institutional and accre
